newsfilter
← Latest News
PR Newswire·

Immunic to Participate in Investor and Medical Conferences in May

  • Immunic, Inc. (Nasdaq: IMUX) will attend the 26th Bio€quity Europe conference in Prague and virtually on May 4-6 & 12-13, 2026, with CEO Daniel Vitt & VP Jessica Breu hosting investor meetings.
  • Immunic management, medical & preclinical teams will attend the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC, from May 27-29, 2026.
  • Three poster presentations on Vidofludimus Calcium data from the Phase 2 CALLIPER trial will be displayed at the CMSC meeting: a late-breaking poster on unified statistical analyses for disability changes & two posters on patient-reported outcomes & safety/tolerability.
  • The company's lead program, vidofludimus calcium (IMU-838), is in Phase 3 trials for relapsing multiple sclerosis with top-line data expected by the end of 2026.
  • Vidofludimus calcium functions as a first-in-class Nurr1 activator & selective DHODH inhibitor, combining neuroprotective, anti-inflammatory, & anti-viral effects.
  • Immunic's pipeline includes earlier-stage programs IMU-856 & IMU-381 targeting neurodegenerative, chronic inflammatory, & autoimmune diseases.
  • The press release includes a standard cautionary statement regarding forward-looking statements & potential risks such as clinical trial results, regulatory approval, & macroeconomic factors.